Earn with Nexo
President Trump signed a proclamation imposing 100% tariffs on imported patented drugs and active pharmaceutical ingredients (APIs), a move that directly affects the Polymarket contract on EU retaliatory tariffs against US goods by September 30, where odds sit at
Market reaction
Trading volume on the EU retaliation contract has been flat, with no face value recorded in the last 24 hours. Zero USDC volume means the market is thin enough that a few large trades could move the price sharply. The term structure shows a larger expected jump in September than December, meaning traders are pricing in a faster EU response rather than a drawn-out one.
Why it matters
Trump framed the proclamation as a national security measure aimed at onshoring pharmaceutical production and reducing dependence on Chinese and Indian supply chains. But the proclamation also includes preferential treatment for allied countries, including the EU, which complicates the retaliation calculus. If the EU views the carve-out as sufficient, retaliation odds stay low. If the EU treats 100% pharma tariffs as a serious trade barrier regardless of the preferential language, odds move up fast. Buying YES at current low prices pays well if the EU responds before September 30, but that bet requires confidence the EU considers these tariffs worth retaliating over on that timeline.
What to watch
Statements from the EU Commission and any actions from the US Trade Representative will be the first signals of whether Brussels moves toward retaliation or negotiation. The gap between the September and December contracts is worth monitoring: if that spread narrows, it suggests traders are pushing their retaliation timeline out.
API access
Get prediction market intelligence as a structured API feed. Early access waitlist.